BioCentury
ARTICLE | Clinical News

ZYC300: Zycos started a U.S. Phase I/II of ZYC300 trial in patients with breast, ovarian, colorectal or prostate cancer

April 22, 2002 7:00 AM UTC

Zycos Inc., Lexington, Mass. Product: ZYC300 Business: Cancer Therapeutic category: Immune modulation Target: Cytochrome P450 1B1 (CYP1B1) Description: DNA vector that induces specific T cell respo...